Effects of formoterol on protein metabolism in myotubes during hyperthermia

Muscle and Nerve

Volumn 43, Issue 2, 2011, Pages 268-273

  Ametller, Elisabet ^a   Busquets, Sílvia ^a   Fuster, Gemma ^a   Figueras, Maria T ^a   Fontes De Oliveira, Cibely Cristine ^a   Toledo, Míriam ^a   Korzeniewska, Katarzyna ^a   Argilés, Josep M ^a   López Soriano, Francisco J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

2 agonists; C2C12 cells; Hyperthermia; Ubiquitin dependent proteolytic system protein degradation

Indexed keywords

ADENYLATE CYCLASE; FORMOTEROL;

ANIMAL CELL; ARTICLE; DRUG EFFECT; HYPERTHERMIA; MOUSE; MUSCLE ATROPHY; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SYNTHESIS;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANALYSIS OF VARIANCE; ANIMALS; CELL LINE, TRANSFORMED; CYCLIC AMP; DDT; ETHANOLAMINES; GENE EXPRESSION REGULATION; HYPERTHERMIA, INDUCED; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR FLUID; MICE; MUSCLE FIBERS, SKELETAL; MYOFIBRILS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITINS;

EID: 78751654795     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21852     Document Type: Article

References (26)

1. Hasselgren PO, Fischer JE. The ubiquitin-proteasome pathway: review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions. Ann Surg 1997; 225:307-316.
2. Llovera M, García-Martínez C, Agell N, Marzábal M, López-Soriano FJ, Argilés JM. Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Lett 1994;338:311-318. (Pubitemid 24056743)
3. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, et al. FoxO3 coordinately activates protein degradation by the autophagic/ lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007;6:472-483. (Pubitemid 350163056)
4. Melstrom LG, Melstrom KA Jr, Ding XZ, Adrian TE. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol 2007;22:805-814.
5. Costelli P, Reffo P, Penna F, Autelli R, Bonelli G, Baccino FM. Ca(2+)-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol 2005;37:2134-2146.
6. Angeras A, Angeras U, Hasselgren PO, Fischer JE. Effects of elevated temperature on protein breakdown in muscle from septic rats. Am J Physiol 1990;258:589-592. (Pubitemid 20140641)
7. Luo GJ, Sun X, Hasselgren PO. Hyperthermia stimulates energy-proteasome- dependent protein degradation in cultured myotubes. Am J Physiol 2000;278:749-756. (Pubitemid 30158137)
8. Smith HJ, Kha AL, Tisdale MJ. Downregulation of ubiquitin-dependent protein degradation in murine myotubes during hyperthermia by eicosapentaenoic acid. Biochem Biophys Res Commun 2005;332:83-88.
9. Stock MJ, Rothwell NJ. Effects of b-adrenergic agonists on metabolism and body composition. In: Buttery PJ, Hayes NB, Lindsay DB, editors. Control and manipulation of animal growth. London: Butterworths; 1985. p 249-257.
10. Kim YS, Sainz RD. Beta-adrenergic agonists and hypertrophy of skeletal muscles. Life Sci 1992;50:397-407.
11. Agbenyega ET, Wareham AC. Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone. Comp Biochem Physiol Comp Physiol 1992;102:141-145.
12. Rajab P, Fox J, Riaz S, Tomlinson D, Ball D, Greenhaff PL. Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. Am J Physiol Regul Integr Comp Physiol 2000;279:1076-1081.
13. Hinkle RT, Hodge KM, Cody DB, Sheldon RJ, Kobilka BK, et al. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve 2002;25:729-734.
14. Wineski LE, von Deutsch DA, Abukhalaf IK, Pitts SA, Potter DE, Paulsen DF. Muscle-specific effects of hindlimb suspension and clenbuterol in mature male rats. Cells Tissues Organs 2002;171:188-198. (Pubitemid 34827777)
15. Yang YT, McElligot MA. Multiple actions of β-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J 1989;261:1-10. (Pubitemid 19174752)
16. Mersmann HJ. Overview of the effects of beta-adrenergic receptor agonists on animal growth including mechanisms of action. J Anim Sci 1998;76:160-172.
17. Anderson GP. Pharmacology of formoterol: an innovative bronchodilator. Agents Actions 1991;34(suppl):97-115.
18. Mahler DA. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2002;110(suppl):S298-S303. (Pubitemid 35471719)
19. Brusasco V, Crimi E, Gherson G, Nardelli R, Oldani V, Francucci B, et al. Actions other than smooth muscle relaxation may play a role in the protective effects of formoterol on the allergen-induced late asthmatic reaction. Pulm Pharmacol Ther 2002;15:399-406.
20. Linden A, Bergendal A, Ullman A, Skoogh BE, Lofdahl CG. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993;48:547-553. (Pubitemid 23160174)
21. Busquets S, Figueras MT, Fuster G, Almendro V, Moore-Carrasco R, Ametller E, et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004;64:6725-6731. (Pubitemid 39297935)
22. Alvarez B, Quinn LS, Busquets S, Lopez-Soriano FJ, Argiles JM. Direct effects of tumor necrosis factor alpha (TNF-alpha) on murine skeletal muscle cell lines. Bimodal effects on protein metabolism, Eur Cytokine Netw 2001;12:399-410.
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159. (Pubitemid 17064313)
24. Hightower LE. Heat shock, stress proteins, chaperones, and proteo-toxicity. Cell 1991;66:191-197. (Pubitemid 121001359)
25. Feige U, van Eden W. Infection, autoimmunity and autoimmune disease. EXS 1996;77:359-373.
26. Gething MJ. Protein folding. The difference with prokaryotes. Nature 1997;388:329-331